ATYRaTyr Pharma, Inc.

$89M

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$11M

Net Income

-$11M

EPS (Diluted)

$-5.40

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$89M

Total Liabilities

$25M

Stockholders' Equity

$64M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$11M	-$13M	+10.6%
Net Income	-$11M	-$13M	+8.7%

ATYR Q4 2017 Earnings — aTyr Pharma, Inc. Revenue & Financial Results | Market Cap Arena